World's Best Scientists 2026 revealed!
Eric Van Cutsem

Eric Van Cutsem

Award Badge
Best Scientists
2025
Award Badge
Medicine
Belgium
2026

D-Index & Metrics

Best Scientists

D-Index
186
Citations
190330
World Ranking
479
National Ranking
3

Medicine

D-Index
192
Citations
204174
World Ranking
238
National Ranking
3

Eric Van Cutsem publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric Van Cutsem sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,742 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eric Van Cutsem D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric Van Cutsem sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 192 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Belgium Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in Belgium Leader Award
  • 2023 - Research.com Medicine in Belgium Leader Award
  • 2022 - Research.com Medicine in Belgium Leader Award

Overview

Eric Van Cutsem is affiliated with KU Leuven in Belgium and has a research focus rooted in medicine, particularly oncology. Their body of work spans over 1,000 publications, with significant contributions to oncology, pulmonary and respiratory medicine, surgery, pathology and forensic medicine, and cancer research.

Their research emphasizes several main topics, including colorectal cancer treatments and studies, gastric cancer management and outcomes, cancer immunotherapy and biomarkers, pancreatic and hepatic oncology research, esophageal cancer research and treatment, genetic factors in colorectal cancer, and cancer genomics and diagnostics.

Eric Van Cutsem has published extensively in prominent scientific journals. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • New England Journal of Medicine
  • European Journal of Cancer

Their recent notable papers demonstrate engagement with clinical oncology and cancer immunotherapy topics. These papers include:

  • "Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer," 2020, New England Journal of Medicine
  • "Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer," 2021, New England Journal of Medicine
  • "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study," 2020, The Lancet Oncology
  • "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer," 2020, JAMA Oncology
  • "The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer," 2021, Nature

The scientist frequently collaborates with several researchers in their field, with the top co-authors being:

  • Josep Tabernero
  • Takayuki Yoshino
  • Kohei Shitara
  • Thierry André
  • Sara Lonardi

Eric Van Cutsem's work covers a wide range of clinical and translational research within oncology, combining studies on immunotherapy, genetic factors, and treatment outcomes in various gastrointestinal cancers.

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

    Eric Van Cutsem;Claus Henning Köhne;Erika Hitre;Jerzy Zaluski

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    James C. Yao;Manisha H. Shah;Tetsuhide Ito;Catherine Lombard Bohas

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

    Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

    Eric Van Cutsem;Vladimir M. Moiseyenko;Sergei Tjulandin;Alejandro Majlis

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

    Thierry André;Kai-Keen Shiu;Tae Won Kim;Benny Vittrup Jensen

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Sabine Tejpar
Sabine Tejpar KU Leuven
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Marc Peeters
Marc Peeters University of Antwerp
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Thierry André
Thierry André Université Paris Cité
Alfredo Falcone
Alfredo Falcone University of Pisa
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a career in medicine, a range of related online degrees can broaden your opportunities within healthcare. For those interested in managing healthcare facilities or leading teams, online healthcare administration programs offer flexibility and industry-focused training.

Earning a master’s degree is a common path for career advancement. You can explore some of the cheapest online mha programs to obtain advanced credentials at a more affordable cost.

For nurses seeking to reach the highest clinical levels, Doctor of Nursing Practice (DNP) programs are increasingly available online. Take a look at the cheapest dnp options to advance your nursing career without leaving your current job.

Aspiring pharmacists can also benefit from distance learning. Programs such as pharmacy school online accredited allow you to earn your degree with greater convenience while ensuring proper accreditation.

Choosing the right online degree can open doors to leadership, research, or advanced practice roles in healthcare—providing flexibility and cost savings along the way.

Best Scientists Citing Eric Van Cutsem

Trending Scientists

Recently Published Articles